Similar articles for PMID: 30858416

Year	Number of Results
2003	2
2005	4
2006	1
2007	5
2008	6
2009	4
2011	5
2012	3
2013	5
2014	3
2015	3
2016	9
2017	8
2018	1
2019	7
2020	4
2021	3
2022	2
2024	0

1

Physical plasma-triggered ROS induces tumor cell death upon cleavage of HSP90 chaperone.

Bekeschus S, Lippert M, Diepold K, Chiosis G, Seufferlein T, Azoitei N. Bekeschus S, et al. Sci Rep. 2019 Mar 11;9(1):4112. doi: 10.1038/s41598-019-38580-0. Sci Rep. 2019. PMID: 30858416 Free PMC article.

2

Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2.

Chen L, Liu Y, Becher A, Diepold K, Schmid E, Fehn A, Brunner C, Rouhi A, Chiosis G, Cronauer M, Seufferlein T, Azoitei N. Chen L, et al. Carcinogenesis. 2020 Oct 15;41(10):1421-1431. doi: 10.1093/carcin/bgaa001. Carcinogenesis. 2020. PMID: 31917403 Free PMC article.

3

Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells.

Park S, Park JA, Yoo H, Park HB, Lee Y. Park S, et al. Redox Biol. 2017 Oct;13:470-476. doi: 10.1016/j.redox.2017.07.010. Epub 2017 Jul 12. Redox Biol. 2017. PMID: 28715732 Free PMC article.

4

Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.

Park SE, Kim DE, Kim MJ, Lee JS, Rho JK, Jeong SY, Choi EK, Kim CS, Hwang JJ. Park SE, et al. Oncol Rep. 2019 Jan;41(1):525-533. doi: 10.3892/or.2018.6814. Epub 2018 Oct 22. Oncol Rep. 2019. PMID: 30365122

5

HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.

Guo A, Lu P, Lee J, Zhen C, Chiosis G, Wang YL. Guo A, et al. Oncogene. 2017 Jun 15;36(24):3441-3449. doi: 10.1038/onc.2016.494. Epub 2017 Jan 23. Oncogene. 2017. PMID: 28114285 Free PMC article.

6

Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.

Giulino-Roth L, van Besien HJ, Dalton T, Totonchy JE, Rodina A, Taldone T, Bolaender A, Erdjument-Bromage H, Sadek J, Chadburn A, Barth MJ, Dela Cruz FS, Rainey A, Kung AL, Chiosis G, Cesarman E. Giulino-Roth L, et al. Mol Cancer Ther. 2017 Sep;16(9):1779-1790. doi: 10.1158/1535-7163.MCT-16-0848. Epub 2017 Jun 15. Mol Cancer Ther. 2017. PMID: 28619753 Free PMC article.

7

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.

Rouhi A, Miller C, Grasedieck S, Reinhart S, Stolze B, Döhner H, Kuchenbauer F, Bullinger L, Fröhling S, Scholl C. Rouhi A, et al. Oncotarget. 2017 Jan 31;8(5):7678-7690. doi: 10.18632/oncotarget.13841. Oncotarget. 2017. PMID: 28032595 Free PMC article.

8

Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.

Gallerne C, Prola A, Lemaire C. Gallerne C, et al. Biochim Biophys Acta. 2013 Jun;1833(6):1356-66. doi: 10.1016/j.bbamcr.2013.02.014. Epub 2013 Feb 26. Biochim Biophys Acta. 2013. PMID: 23485394 Free article.

9

Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Donnelly A, Blagg BS. Donnelly A, et al. Curr Med Chem. 2008;15(26):2702-17. doi: 10.2174/092986708786242895. Curr Med Chem. 2008. PMID: 18991631 Free PMC article. Review.

10

PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.

Li HK, Matsumoto Y, Furusawa Y, Kamada T. Li HK, et al. J Radiat Res. 2016 Sep;57(5):572-575. doi: 10.1093/jrr/rrw054. Epub 2016 May 29. J Radiat Res. 2016. PMID: 27242340 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

65 results

Results by year